It remains to be determined if VEGFA and its receptor VEGFR2 and VEGFC and its receptor VEGFR3, and CSF2 and its receptor GMRA/GMRB can also serve as therapeutic targets for HER2+ breast cancer since the associations we found were modest. This evidence concerns the gene CSF2 and breast carcinoma.